Evaluation of antifungal effect of grape seed extract (Gse) on candida glabrata and candida krusei: In vitro study
چکیده
Background: Recently, following the widespread use of broad-spectrum antibiotics and immunosuppressive treatments, the prevalence of mucosal and systemic infections caused by glabrata and Candida krusei has been increased significantly. On the other hand, in addition to the problems caused by side effects of common antifungal drugs, the conducted studies have been indicative of the failure of antifungal treatments on Candidiasis different clinical infections and drug resistance including triazoles group (e.g., fluconazole) in the long-term use of them, especially in patients with a weakened immune system problem. Objective: Comparing the antifungal effect of grape seed extract with fluconazole and Nystatin on glabrata and Candida krusei in vitro Material and methods: In the present study, to review the antifungal effect and to determine MIC (the Minimum Inhibitory Concentration of growth) of grape seed extract, CLSI (Clinical and Laboratory Standards Institute) has been used. To ensure the correctness of the findings of macro dilution method, agar well diffusion method has been used. Finally, the obtained results are analyzed using SPSS 16 software. Findings: MIC of grape seed extract was 50 آµg/ml for glabrata and Candida krusei. On the other hand, in evaluation of the effect of different concentrations of grape seed extract with well diffusion of Candida krusei method was almost equal to Candida glabrata in same concentrations. As a result, the results related to both well diffusion methods (agar well diffusion) and the maximum inhibitory concentration MIC (macro dilution) are confirming the same antimicrobial susceptibility of both glabrata and Candida krusei to GSE. Conclusion: Grape seed extract having benefits like low price, being available, suitable taste rather than Nystatin, and fewer side effects can be a good Candidate as antifungal drug to against infections caused by glabrata and Candida krusei, after clinical trial. é 2018, Scientific Publishers of India. All rights reserved.